European Organisation For Research And Treatment Of Cancer - Eortc
Clinical trials sponsored by European Organisation For Research And Treatment Of Cancer - Eortc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a pill replace chemo for older breast cancer patients? Results expected Sep 2026 (estimated)
- Scientists launch global study to unlock secrets of male breast cancer Results expected Dec 2026 (estimated)
- New hope for tough brain tumors: targeted radiation trial launches Results expected Apr 2027 (estimated)
- Could chemo before surgery beat sarcoma? new trial aims to find out Results expected Apr 2027 (estimated)
- New combo therapy aims to slow head and neck cancer spread Results expected Jul 2027 (estimated)
-
Can a new drug boost radiation's power against head and neck cancer in older patients?
Disease control Stopped earlyThis phase II trial is investigating whether adding the experimental drug xevinapant to standard radiation therapy can improve outcomes for adults aged 70 and older with locally advanced head and neck cancer. Participants are randomly assigned to receive either xevinapant or a pl…
Phase 2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Tailored therapy for medulloblastoma shows promise but trial cut short
Disease control Stopped earlyThis phase 2 trial tested a personalized treatment approach for post-pubertal patients with newly diagnosed medulloblastoma, a rare brain cancer. The experimental group received a targeted drug called sonidegib along with reduced radiation, based on the tumor's genetic subtype. T…
Phase 2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Mesothelioma drug trial halted early – what we know
Disease control Stopped earlyThis phase 2 trial tested whether the drug nintedanib could help people with malignant pleural mesothelioma keep their cancer from growing after initial chemotherapy. 37 patients were randomly assigned to receive either nintedanib or a placebo twice daily. The study was terminate…
Phase 2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 26, 2026 18:48 UTC